#health India’s Covaxin COVID-19 vaccine 77.8% effective, Lancet study finds.
A new study in The Lancet is offering the first peer-reviewed and published data on the efficacy of Covaxin, a COVID-19 vaccine developed in India. The vaccine was found to be 77.8 percent effective at preventing symptomatic COVID-19 in a large Phase 3 clinical trial (more than 25,000 subjects, randomly allocated either two doses of the vaccine (administered four weeks apart) or two doses of placebo). No serious adverse events were detected in the trial.
https://newatlas.com/health-wellbeing/india-covaxin-coronavirus-vaccine-effective-study-trial-results/
A new study in The Lancet is offering the first peer-reviewed and published data on the efficacy of Covaxin, a COVID-19 vaccine developed in India. The vaccine was found to be 77.8 percent effective at preventing symptomatic COVID-19 in a large Phase 3 clinical trial (more than 25,000 subjects, randomly allocated either two doses of the vaccine (administered four weeks apart) or two doses of placebo). No serious adverse events were detected in the trial.
https://newatlas.com/health-wellbeing/india-covaxin-coronavirus-vaccine-effective-study-trial-results/